JP2013530958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530958A5 JP2013530958A5 JP2013513401A JP2013513401A JP2013530958A5 JP 2013530958 A5 JP2013530958 A5 JP 2013530958A5 JP 2013513401 A JP2013513401 A JP 2013513401A JP 2013513401 A JP2013513401 A JP 2013513401A JP 2013530958 A5 JP2013530958 A5 JP 2013530958A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- pharmaceutically acceptable
- oxopiperidin
- methylbutan
- isopropylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DRLCSJFKKILATL-YWCVFVGNSA-N 2-[(3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2s)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid Chemical compound C1([C@@H]2[C@H](N(C([C@@](C)(CC(O)=O)C2)=O)[C@H](CS(=O)(=O)C(C)C)C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC(Cl)=C1 DRLCSJFKKILATL-YWCVFVGNSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35182710P | 2010-06-04 | 2010-06-04 | |
| US61/351,827 | 2010-06-04 | ||
| US35232210P | 2010-06-07 | 2010-06-07 | |
| US61/352,322 | 2010-06-07 | ||
| US201161452578P | 2011-03-14 | 2011-03-14 | |
| US61/452,578 | 2011-03-14 | ||
| PCT/US2011/039184 WO2011153509A1 (en) | 2010-06-04 | 2011-06-03 | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013192621A Division JP5908446B2 (ja) | 2010-06-04 | 2013-09-18 | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530958A JP2013530958A (ja) | 2013-08-01 |
| JP2013530958A5 true JP2013530958A5 (enExample) | 2013-11-07 |
| JP5420797B2 JP5420797B2 (ja) | 2014-02-19 |
Family
ID=44504412
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513401A Active JP5420797B2 (ja) | 2010-06-04 | 2011-06-03 | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 |
| JP2013192621A Active JP5908446B2 (ja) | 2010-06-04 | 2013-09-18 | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 |
| JP2016056518A Active JP6077695B2 (ja) | 2010-06-04 | 2016-03-22 | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013192621A Active JP5908446B2 (ja) | 2010-06-04 | 2013-09-18 | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 |
| JP2016056518A Active JP6077695B2 (ja) | 2010-06-04 | 2016-03-22 | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 |
Country Status (41)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US20130267699A1 (en) | 2011-06-24 | 2013-10-10 | California Institute Of Technology | Quaternary heteroatom containing compounds |
| US8822679B2 (en) * | 2011-06-24 | 2014-09-02 | California Institute Of Technology | Quaternary heteroatom containing compounds |
| MX352672B (es) * | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| ES2596215T3 (es) | 2011-10-24 | 2017-01-05 | Asana Biosciences, Llc | Ciclohexilaminas |
| US9376409B2 (en) | 2012-05-09 | 2016-06-28 | Boehringer Ingelheim International Gmbh | Methods for making oxetan-3-ylmethanamines |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| US20160002185A1 (en) * | 2013-02-19 | 2016-01-07 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) * | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| WO2014151863A1 (en) * | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| MA53572A1 (fr) * | 2013-06-10 | 2021-10-29 | Amgen Inc | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
| MY192088A (en) * | 2013-11-11 | 2022-07-26 | Amgen Inc | Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
| EP3077004B1 (en) * | 2013-12-05 | 2020-02-19 | F.Hoffmann-La Roche Ag | Novel combination treatment for acute myeloid leukemia (aml) |
| AU2015247646B2 (en) | 2014-04-17 | 2019-06-06 | The Regents Of The University Of Michigan | MDM2 inhibitors and therapeutic methods using the same |
| CN103992334A (zh) * | 2014-05-29 | 2014-08-20 | 中国人民解放军第二军医大学 | 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法 |
| WO2016001376A1 (en) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| JP6591532B2 (ja) | 2014-08-21 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| US10421696B2 (en) | 2014-12-18 | 2019-09-24 | California Institute Of Technology | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation |
| CN107922373A (zh) | 2015-03-27 | 2018-04-17 | 加利福尼亚技术学院 | 使用低催化剂浓度和稳定的预催化剂的不对称催化脱羧烷基烷基化 |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| HUE054985T2 (hu) * | 2015-10-09 | 2021-11-29 | Boehringer Ingelheim Int | Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok |
| EP3426391A4 (en) | 2016-03-11 | 2019-08-28 | California Institute of Technology | COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| AU2017250076B2 (en) * | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP3480190B1 (en) | 2017-11-01 | 2023-01-04 | California Institute of Technology | Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols |
| EP3759090A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| IL319432A (en) | 2018-04-30 | 2025-05-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| CA3110525A1 (en) | 2018-08-31 | 2020-03-05 | Amgen, Inc. | Processes for preparing a mdm2 inhibitor |
| CN110963958B (zh) | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| EP3699173A1 (en) | 2018-10-18 | 2020-08-26 | California Institute of Technology | Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same |
| WO2020123656A1 (en) * | 2018-12-11 | 2020-06-18 | Kartos Therapeutics | Methods and compositions of treating an ophthalmic condition |
| GB201919219D0 (en) | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| US20230064976A1 (en) * | 2020-01-23 | 2023-03-02 | Ascentage Pharma (Suzhou) Co., Ltd. | Amorphous form or crystalline form of 2-indolinolinololylspironone compounds or their salts, solvent complexes |
| WO2021170881A1 (en) | 2020-02-27 | 2021-09-02 | Syngenta Crop Protection Ag | Pesticidally active diazine-bisamide compounds |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| JP2023539867A (ja) | 2020-08-27 | 2023-09-20 | 大塚製薬株式会社 | Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー |
| CN112213428A (zh) * | 2020-10-13 | 2021-01-12 | 辽宁科技大学 | 一种超临界co2中进行非催化乙酰基化反应及其在线检测方法 |
| US12569564B2 (en) | 2021-01-23 | 2026-03-10 | Newave Pharmaceutical Inc. | Spirocyclic MDM2 modulator and uses thereof |
| WO2022183006A1 (en) | 2021-02-25 | 2022-09-01 | Mayo Foundation For Medical Education And Research | Compounds for programmable protein degradation and methods of use for the disease treatment |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| US20260014260A1 (en) * | 2022-05-24 | 2026-01-15 | Newave Pharmaceutical Inc. | Mdm2 degrader |
| WO2023239697A1 (en) * | 2022-06-06 | 2023-12-14 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| CN115322126B (zh) * | 2022-09-13 | 2023-04-28 | 九江学院 | 一种多芳烃类化合物及其制备方法和应用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH436295A (de) | 1961-11-13 | 1967-05-31 | Mcneilab Inc | Verfahren zur Herstellung neuer 3-Morpholinone |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| AU711832B2 (en) | 1994-08-19 | 1999-10-21 | Abbvie Bahamas Ltd. | Endothelin antagonists |
| ES2259803T3 (es) | 1996-02-13 | 2006-10-16 | Abbott Laboratories | Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina. |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| HUP0003484A3 (en) | 1997-08-04 | 2002-02-28 | Abbott Lab | Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists |
| AU1910299A (en) | 1997-12-18 | 1999-07-05 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| US7214540B2 (en) | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
| US6630006B2 (en) | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
| US7195670B2 (en) | 2000-06-27 | 2007-03-27 | California Institute Of Technology | High throughput screening of crystallization of materials |
| US7052545B2 (en) | 2001-04-06 | 2006-05-30 | California Institute Of Technology | High throughput screening of crystallization of materials |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| US7229500B2 (en) | 2000-11-20 | 2007-06-12 | Parallel Synthesis Technologies, Inc. | Methods and devices for high throughput crystallization |
| HUP0304058A2 (hu) | 2001-01-30 | 2004-04-28 | Bristol-Myers Squibb Company | Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
| CA2446380A1 (en) | 2001-05-08 | 2002-11-14 | Yale University | Proteomimetic compounds and methods |
| WO2002094787A1 (en) | 2001-05-23 | 2002-11-28 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| KR100650966B1 (ko) | 2001-12-18 | 2006-11-30 | 에프. 호프만-라 로슈 아게 | 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도 |
| US6860940B2 (en) | 2002-02-11 | 2005-03-01 | The Regents Of The University Of California | Automated macromolecular crystallization screening |
| US6916833B2 (en) * | 2003-03-13 | 2005-07-12 | Hoffmann-La Roche Inc. | Substituted piperidines |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| KR20080027969A (ko) | 2004-05-18 | 2008-03-28 | 에프. 호프만-라 로슈 아게 | 신규 ｃｉｓ-이미다졸린 |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| JP4931823B2 (ja) | 2004-10-18 | 2012-05-16 | アムジエン・インコーポレーテツド | チアジアゾール化合物及び使用方法 |
| KR101139263B1 (ko) | 2005-03-16 | 2012-05-16 | 에프. 호프만-라 로슈 아게 | 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의그의 용도 |
| JP5180816B2 (ja) | 2005-04-04 | 2013-04-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患および認知症のためのジヒドロピリジン化合物 |
| CN101316823B (zh) | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| MX2008009060A (es) * | 2006-01-13 | 2008-09-26 | Schering Corp | Diaril piperidinas como moduladores de cb1. |
| AU2007207743B2 (en) | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| GB0606283D0 (en) | 2006-03-29 | 2006-05-10 | Cyclacel Ltd | Process |
| WO2008005268A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| CA2657034A1 (en) | 2006-07-19 | 2008-01-24 | University Of Georgia Research Foundation, Inc. | Pyridinone diketo acids: inhibitors of hiv replication in combination therapy |
| US7618989B2 (en) | 2006-08-15 | 2009-11-17 | Wyeth | Tricyclic oxazolidone derivatives useful as PR modulators |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| US8820639B2 (en) | 2006-11-03 | 2014-09-02 | Assa Abloy Ab | Security feature RFID card |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| AR065709A1 (es) * | 2007-03-12 | 2009-06-24 | Biolipox Ab | Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion. |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| CA2680783C (en) | 2007-03-23 | 2012-04-24 | Amgen Inc. | Heterocyclic compounds and their uses |
| MX2009010050A (es) | 2007-03-23 | 2009-10-12 | Amgen Inc | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). |
| HRP20160350T1 (hr) | 2007-03-23 | 2016-05-06 | Amgen Inc. | Heterociklički spojevi i njihove uporabe |
| BRPI0810082A2 (pt) * | 2007-03-29 | 2014-10-21 | Novartis Ag | 3-imidazolil-indóis para o tratamento de doenças proliferativas |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| WO2009007750A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| US7919504B2 (en) | 2007-07-17 | 2011-04-05 | Amgen Inc. | Thiadiazole modulators of PKB |
| US7928140B2 (en) | 2007-08-02 | 2011-04-19 | Amgen Inc. | Benzothiazole PI3 kinase modulators for cancer treatment |
| WO2009047161A1 (en) | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
| US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| EP2222296A2 (en) | 2007-12-26 | 2010-09-01 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| EP2268616A1 (en) | 2008-03-21 | 2011-01-05 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| ATE531372T1 (de) | 2008-04-07 | 2011-11-15 | Amgen Inc | Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren |
| JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| AR073578A1 (es) * | 2008-09-15 | 2010-11-17 | Priaxon Ag | Pirrolidin-2-onas |
| CA2734363C (en) | 2008-09-18 | 2016-10-25 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
| WO2010083246A1 (en) | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| MX2011008674A (es) | 2009-02-18 | 2011-11-04 | Amgen Inc | Compuestos de indol/bencimidazol como inhibidores de quinasa mtor. |
| CA2755285C (en) | 2009-03-20 | 2014-02-11 | Yunxin Y. Bo | Inhibitors of pi3 kinase |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| CA2760778A1 (en) | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| EP2445902A2 (en) | 2009-06-25 | 2012-05-02 | Amgen, Inc | Heterocyclic compounds and their uses as inhibitors of pi3k activity |
| CN102625799A (zh) | 2009-06-25 | 2012-08-01 | 安姆根有限公司 | 杂环化合物及其用途 |
| JP2012531435A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | ＰＩ３Ｋ阻害剤としての４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン誘導体 |
| CA2781865A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| EA201200321A1 (ru) | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| US20160002185A1 (en) | 2013-02-19 | 2016-01-07 | Amgen Inc. | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| MA53572A1 (fr) | 2013-06-10 | 2021-10-29 | Amgen Inc | Procédés de production et formes cristallines d'un inhibiteur mdm2 |
-
2011
- 2011-06-02 JO JOP/2011/0182A patent/JO2998B1/ar active
- 2011-06-03 PL PL15159363T patent/PL2927213T3/pl unknown
- 2011-06-03 BR BR122020013151-9A patent/BR122020013151B1/pt active IP Right Grant
- 2011-06-03 KR KR1020207014861A patent/KR20200063255A/ko not_active Ceased
- 2011-06-03 TW TW104140967A patent/TWI582076B/zh active
- 2011-06-03 HR HRP20150704TT patent/HRP20150704T1/hr unknown
- 2011-06-03 PH PH12016501048A patent/PH12016501048A1/en unknown
- 2011-06-03 CN CN201510205985.6A patent/CN105153014B/zh active Active
- 2011-06-03 ME MEP-2019-41A patent/ME03322B/me unknown
- 2011-06-03 SG SG10202006923RA patent/SG10202006923RA/en unknown
- 2011-06-03 ES ES18197155T patent/ES2971445T3/es active Active
- 2011-06-03 RS RS20190184A patent/RS58366B1/sr unknown
- 2011-06-03 JP JP2013513401A patent/JP5420797B2/ja active Active
- 2011-06-03 UY UY0001033430A patent/UY33430A/es unknown
- 2011-06-03 HR HRP20240055TT patent/HRP20240055T1/hr unknown
- 2011-06-03 SI SI201130499T patent/SI2576510T1/sl unknown
- 2011-06-03 PT PT181971557T patent/PT3483143T/pt unknown
- 2011-06-03 IL IL317703A patent/IL317703A/en unknown
- 2011-06-03 FI FIEP18197155.7T patent/FI3483143T3/fi active
- 2011-06-03 DK DK11726581.9T patent/DK2576510T3/en active
- 2011-06-03 KR KR1020197014475A patent/KR20190058694A/ko not_active Ceased
- 2011-06-03 DK DK15159363.9T patent/DK2927213T3/en active
- 2011-06-03 CA CA3060703A patent/CA3060703C/en active Active
- 2011-06-03 SI SI201132100T patent/SI3483143T1/sl unknown
- 2011-06-03 SM SM20190099T patent/SMT201900099T1/it unknown
- 2011-06-03 KR KR1020217016376A patent/KR20210068144A/ko not_active Ceased
- 2011-06-03 BR BR112012030923A patent/BR112012030923B8/pt active IP Right Grant
- 2011-06-03 PE PE2012002267A patent/PE20130229A1/es active IP Right Grant
- 2011-06-03 AU AU2011261263A patent/AU2011261263C1/en active Active
- 2011-06-03 EP EP18197155.7A patent/EP3483143B1/en active Active
- 2011-06-03 KR KR1020137000287A patent/KR101456801B1/ko active Active
- 2011-06-03 ES ES11726581.9T patent/ES2540992T3/es active Active
- 2011-06-03 RS RS20240056A patent/RS65141B1/sr unknown
- 2011-06-03 KR KR1020227017268A patent/KR20220083817A/ko not_active Ceased
- 2011-06-03 CA CA3207676A patent/CA3207676A1/en active Pending
- 2011-06-03 NZ NZ604074A patent/NZ604074A/en unknown
- 2011-06-03 UY UY0001039338A patent/UY39338A/es not_active Application Discontinuation
- 2011-06-03 KR KR1020257008612A patent/KR20250044461A/ko active Pending
- 2011-06-03 CN CN201180038476.9A patent/CN103180296B/zh active Active
- 2011-06-03 SG SG10202112488SA patent/SG10202112488SA/en unknown
- 2011-06-03 PT PT117265819T patent/PT2576510E/pt unknown
- 2011-06-03 EP EP15159363.9A patent/EP2927213B1/en active Active
- 2011-06-03 ME MEP-2015-84A patent/ME02150B/me unknown
- 2011-06-03 AR ARP110101928A patent/AR082763A1/es active IP Right Grant
- 2011-06-03 IL IL295076A patent/IL295076B2/en unknown
- 2011-06-03 MY MYPI2018000697A patent/MY202394A/en unknown
- 2011-06-03 TW TW100119640A patent/TWI433844B/zh active
- 2011-06-03 HU HUE15159363A patent/HUE041488T2/hu unknown
- 2011-06-03 LT LTEP18197155.7T patent/LT3483143T/lt unknown
- 2011-06-03 EP EP22160459.8A patent/EP4092012A1/en active Pending
- 2011-06-03 UA UAA201300192 patent/UA110481C2/ru unknown
- 2011-06-03 NZ NZ627385A patent/NZ627385A/en unknown
- 2011-06-03 LT LTEP15159363.9T patent/LT2927213T/lt unknown
- 2011-06-03 HU HUE18197155A patent/HUE066050T2/hu unknown
- 2011-06-03 MX MX2016001932A patent/MX343587B/es unknown
- 2011-06-03 KR KR1020147013519A patent/KR101863407B1/ko active Active
- 2011-06-03 MA MA35504A patent/MA34342B1/fr unknown
- 2011-06-03 PL PL11726581T patent/PL2576510T3/pl unknown
- 2011-06-03 TW TW103105903A patent/TWI519519B/zh active
- 2011-06-03 MX MX2012014044A patent/MX337178B/es active IP Right Grant
- 2011-06-03 WO PCT/US2011/039184 patent/WO2011153509A1/en not_active Ceased
- 2011-06-03 SG SG10201604817QA patent/SG10201604817QA/en unknown
- 2011-06-03 DK DK18197155.7T patent/DK3483143T3/da active
- 2011-06-03 SM SM20240024T patent/SMT202400024T1/it unknown
- 2011-06-03 PH PH1/2012/502410A patent/PH12012502410A1/en unknown
- 2011-06-03 EP EP20110726581 patent/EP2576510B1/en active Active
- 2011-06-03 SG SG2012088837A patent/SG186147A1/en unknown
- 2011-06-03 KR KR1020187014728A patent/KR20180059574A/ko not_active Ceased
- 2011-06-03 ES ES15159363T patent/ES2717306T3/es active Active
- 2011-06-03 IL IL277579A patent/IL277579B/en unknown
- 2011-06-03 RS RS20150364A patent/RS54030B1/sr unknown
- 2011-06-03 PL PL18197155.7T patent/PL3483143T3/pl unknown
- 2011-06-03 KR KR1020237037399A patent/KR20230156431A/ko not_active Ceased
- 2011-06-03 EA EA201291356A patent/EA023004B1/ru not_active IP Right Cessation
- 2011-06-03 US US13/153,345 patent/US8569341B2/en active Active
- 2011-06-03 SI SI201131669T patent/SI2927213T1/sl unknown
- 2011-06-03 CA CA3157177A patent/CA3157177C/en active Active
- 2011-06-03 CA CA2799972A patent/CA2799972C/en active Active
- 2011-06-03 PT PT15159363T patent/PT2927213T/pt unknown
-
2012
- 2012-11-22 IL IL223201A patent/IL223201A/en active IP Right Grant
- 2012-11-27 TN TNP2012000559A patent/TN2012000559A1/en unknown
- 2012-12-04 CL CL2012003415A patent/CL2012003415A1/es unknown
- 2012-12-10 CO CO12223240A patent/CO6710897A2/es active IP Right Grant
- 2012-12-21 CR CR20120659A patent/CR20120659A/es unknown
-
2013
- 2013-09-12 US US14/025,688 patent/US20140011796A1/en not_active Abandoned
- 2013-09-18 JP JP2013192621A patent/JP5908446B2/ja active Active
-
2014
- 2014-02-07 ZA ZA2014/00948A patent/ZA201400948B/en unknown
- 2014-06-26 IL IL233411A patent/IL233411A/en active IP Right Grant
- 2014-06-26 US US14/316,586 patent/US9296736B2/en active Active
-
2015
- 2015-07-14 SM SM201500168T patent/SMT201500168B/xx unknown
-
2016
- 2016-01-27 US US15/008,342 patent/US9593129B2/en active Active
- 2016-03-22 JP JP2016056518A patent/JP6077695B2/ja active Active
- 2016-06-16 IL IL246296A patent/IL246296A0/en active IP Right Grant
- 2016-07-06 CL CL2016001733A patent/CL2016001733A1/es unknown
-
2017
- 2017-01-23 US US15/412,804 patent/US20170144971A1/en not_active Abandoned
-
2018
- 2018-03-21 US US15/927,426 patent/US20190062276A1/en not_active Abandoned
-
2019
- 2019-02-11 HR HRP20190273TT patent/HRP20190273T1/hr unknown
- 2019-02-13 CY CY20191100192T patent/CY1121265T1/el unknown
- 2019-03-11 IL IL265278A patent/IL265278B/en active IP Right Grant
-
2020
- 2020-08-03 US US16/983,027 patent/US20210179560A1/en not_active Abandoned
-
2022
- 2022-02-15 US US17/672,660 patent/US20220169611A1/en not_active Abandoned
-
2023
- 2023-10-11 US US18/484,675 patent/US20240300892A1/en not_active Abandoned
-
2025
- 2025-03-04 US US19/070,108 patent/US20260078091A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USD675268S1 (en) | Ball | |
| JP2014515013A5 (enExample) | ||
| EA201490419A1 (ru) | Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания | |
| JP2013532687A5 (enExample) | ||
| JP2013519683A5 (enExample) | ||
| USD670089S1 (en) | Table | |
| NL300909I2 (nl) | Ribociclib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| JP2010529118A5 (enExample) | ||
| JP2015504870A5 (enExample) | ||
| EP2881384A8 (en) | Partially saturated nitrogen-containing heterocyclic compound | |
| NL300971I2 (nl) | Eravacycline, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| WO2012137982A3 (en) | Sulfonamide derivative and use thereof | |
| JP2011168603A5 (enExample) | ||
| NL301191I2 (nl) | voxelotor of een tautomeer of farmaceutisch aanvaardbaar zout daarvan | |
| JP2013525444A5 (enExample) | ||
| JP2013514381A5 (enExample) | ||
| JP2011105738A5 (enExample) | ||
| HK1198359A1 (en) | Carrier-linked treprostinil prodrugs | |
| WO2012020848A8 (en) | Heterocyclic compound and use thereof | |
| PH12015502705B1 (en) | Processes of making and crystalline forms of a mdm2 inhibitor | |
| JP2013507408A5 (enExample) | ||
| JP2012519182A5 (enExample) | ||
| JP2013532130A5 (enExample) | ||
| JP2009538861A5 (enExample) | ||
| JP2011219478A5 (enExample) |